There are 807 resources available
326P - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
Presenter: Byoung Chul Cho
Session: Poster viewing 05.
328P - Long-term follow-up of pembrolizumab plus chemotherapy in Chinese patients with metastatic squamous non-small cell lung cancer (NSCLC) from KEYNOTE-407
Presenter: Ying Cheng
Session: Poster viewing 05.
329P - ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib
Presenter: Jonathan Riess
Session: Poster viewing 05.
332P - A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR mutant cohort
Presenter: Wen Feng Fang
Session: Poster viewing 05.
333P - Efficacy and safety of immune checkpoint inhibitors alone or combined with chemotherapy in pulmonary sarcomatoid carcinoma
Presenter: Hiroyasu Kaneda
Session: Poster viewing 05.
334P - Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1
Presenter: Gwo Fuang Ho
Session: Poster viewing 05.
335P - Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)
Presenter: Hiroshi Yokouchi
Session: Poster viewing 05.
336P - Spatial characterisation of immune microenvironment in malignant pleural mesothelioma
Presenter: Dmitrii Shek
Session: Poster viewing 05.